Anti-CD22 immunotoxins, being tested in hairy cell leukemia Antibody-drug conjugates, most, if not all, are immunotoxins but ... an immunotoxin used to treat T cell leukemias Resimmune, or A-dmDT390-bisFv(UCHT1), an experimental anti-T cell immunotoxin in ... An immunotoxin is an artificial protein consisting of a targeting portion linked to a toxin. When the protein binds to that ... Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (July 2006). "Immunotoxin therapy of cancer". Nat. Rev. Cancer. 6 (7): 559-65. ...

An anti-CD22 immunotoxin is a monoclonal antibody (targeting CD22) linked to a cytotoxic agent. They are being studied in the ... CAT-3888 (or BL22) is an anti-CD22 immunotoxin and completed a Phase I clinical (human) trial for the treatment of hairy cell ... "Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia. -- Kreitman et al. 28 (15): ... CAT-3888 was succeeded by moxetumomab pasudotox (CAT-8015, HA22), an anti-CD22 immunotoxin comprising a modified Pseudomonas ...

... is made in the laboratory. It binds to CD19, a protein on the surface of normal B cells and B-cell tumors ... Anti-CD19 immunotoxin is a monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types ... Anti-CD19 immunotoxin entry in the public domain NCI Dictionary of Cancer Terms This article incorporates public domain ...

The Recombinant Immunotoxin Collaborative Group (RICG) is a group of scientists specialising in immunology, biochemistry and ... The group is working toward the development of genetically engineered immunotoxins made from monoclonal antibody fragments ... The RICG was successful in producing a range of recombinant immunotoxins based on the monoclonal antibodies 4KB128 and OKT10 ... central Italy with the intention of developing one of the RICG produced recombinant immunotoxins for investigation in early ...

In 2010 in vitro experiments proved this concept of IAA as an immunotoxin when used in preclinical studies of targeted cancer ... cited in: Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I (2014). "Immunotoxins for leukemia". Blood. 123 (16): 2470-7. doi: ...

Weldon JE, Pastan I (December 2011). "A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin ... Kreitman RJ (October 1999). "Immunotoxins in cancer therapy". Current Opinion in Immunology. 11 (5): 570-8. doi:10.1016/s0952- ...

Manoukian G, Hagemeister F (November 2009). "Denileukin diftitox: a novel immunotoxin". Expert Opinion on Biological Therapy. 9 ...

Furthermore, since immunotoxin treatment to kill starburst amacrine cells shows no difference in the formation of eye-specific ... Immunotoxins can be used to target starburst amacrine cells. Starburst amacrine cells are retinal interneurons responsible for ... Calcium imaging observation following immunotoxin use showed that some correlated firing still remained where coupled voltage ... use of immunotoxins that eliminate certain classes of amacrine cells, or use of knockout mouse lines that have altered ...

Mycotoxins can be categorized as nephrotoxins, hepatoxins, immunotoxins, neurotoxins, etc. Generic groups created by cell ...

Immunotoxin treatment inhibits neuroblastoma growth in mice. CAR T cells targeting GPC2 can eliminate tumors in a metastatic ... Immunotoxins and chimeric antigen receptor (CAR) T cells targeting GPC2 have been developed for treating neuroblastoma and ... "GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt ... "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in ...

Another immunotoxin, SS1P, targets the mesothelin antigen. Mesothelin was discovered by Pastan and his colleague Mark ... 5: 208ra147, 2013 Liu, W., Onda, M., Lee, B., Kreitman, R.J., Hassan, R., Xiang, L., and Pastan, I.: Recombinant immunotoxin ... Pastan's current efforts are directed at improving the activity and usefulness of immunotoxins he has developed. One of the ... His current research is focused on developing Recombinant Immunotoxins (RITs) as a new treatment for cancer. Gene splicing ...

Other potential risk factors include mechanical trauma and exposure to immunotoxins. There is no strong evidence for a genetic ...

... targeted immunotherapy with a novel immunotoxin". Current Oncology Reports. 16 (2): 370. doi:10.1007/s11912-013-0370-0. PMC ...

When the conjugates include a toxin see immunotoxin. Goldenberg DM, Sharkey RM (2007). "Novel radiolabeled antibody conjugates ...

Chemolabelled or immunotoxins antibodies are tagged with chemotherapeutic molecules or toxins, respectively. Research has also ...

Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications. New York: Springer. pp. ...

... , sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults ... On 1 November 2005, Cambridge Antibody Technology (CAT) announced it was acquiring two anti-CD22 immunotoxin products from ... Kreitman RJ, Pastan I (October 2011). "Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox". ...

"Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components". Toxins. 3 (12): 848-883. ...

Dosio, F.; Brusa, P.; Cattel, L. (2011). "Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage ...

Immunotoxins consisting of a monoclonal antibody linked to saporin have been developed and evaluated in formal clinical trials ... One disadvantage of these types of immunotoxin for clinical use is their relatively narrow therapeutic window and associated ... 1997). "The unusual stability of saporin, a candidate for the synthesis of immunotoxins". Biochemical and Biophysical Research ... from Gypsophila paniculata have been shown to significantly augment saporin-based immunotoxins directed against human cancer ...

"Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components". Toxins. 3 (12): 848-883. ...

Alewine researches the use of immunotoxin therapeutics in pancreatic cancer. Her lab and clinic are testing and refining two ... Christine Campo Alewine is an American oncologist and biologist researching immunotoxin therapeutics in pancreatic cancer. She ... Christine Alewine - Treating Pancreatic Cancer with New Immunotoxin Strategies". NIH Intramural Research Program. 2019-02-04. ... recombinant immunotoxins that target a protein called mesothelin that is present on the surface of several types of cancer ...

Falini also led the team that generated and used for the first time an immunotoxin directed against the CD30 molecule for the ... "Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin". The Lancet. 339 (8803): 1195-1196. doi:10.1016/ ...

... the first use of an immunotoxin to treat a malignancy; identification of the genes that cause kidney cancer, leading to the ...

... or A-dmDT390-bisFv(UCHT1) is an experimental drug - an anti-T cell immunotoxin - that is being investigated for the ... Resimmune is a bivalent anti-T cell immunotoxin, A-dmDT390-bisFv(UCHT1). The diphtheria toxin moiety has been modified to ... 2010). Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials. Methods Mol. Biol. Vol. 651. pp ... Clinical trial number NCT00611208 for "A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases" at ...

His research is concerned with the development of the next generation of genetically engineered immunotoxins. "The London ... Saporin Immunotoxins, Curr Top Microbiol Immunol, 234, 57-61 (1998) (Articles with short description, Short description is ...

"Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in ... "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in ...

Wang C, Gao W, Feng M, Pastan I, Ho M (May 2017). "Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver ... Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M (March 2015). "Immunotoxin targeting glypican-3 regresses liver ... Fleming BD, Urban DJ, Hall M, Longerich T, Greten T, Pastan I, Ho M (September 2019). "The engineered anti-GPC3 immunotoxin, ... The HN3 human single-domain antibodies have been used to create immunotoxins and chimeric antigen receptor (CAR) T cells for ...

Chimeric antigen receptor (CAR) T cells and Immunotoxins (antibody-cytotoxin fusion proteins) targeting GPC2 inhibit ... "Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in ...

... using antibody-ricin A chain immunotoxins". J Exp Med. 155 (6): 1797-1809. doi:10.1084/jem.155.6.1797. PMC 2186702. PMID ...